Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - entecavir monohydrate is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - entecavir monohydrate is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - entecavir monohydrate is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - valaciclovir hydrochloride 556.275mg equivalent to valaciclovir 500 mg - film coated tablet - 500 mg - active: valaciclovir hydrochloride 556.275mg equivalent to valaciclovir 500 mg excipient: crospovidone indigo carmine aluminium lake magnesium stearate microcrystalline cellulose opadry blue 02c50740 povidone - valaciclovir rbx is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - olanzapine, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose; microcrystalline cellulose; magnesium stearate - - treatment of schizophrenia and related psychoses. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder.. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - olanzapine, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose; hyprolose; microcrystalline cellulose - - treatment of schizophrenia and related psychoses. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder.. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - olanzapine, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; magnesium stearate - - treatment of schizophrenia and related psychoses. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder.. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - olanzapine, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose; hyprolose - - treatment of schizophrenia and related psychoses. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder.. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - valaciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; indigo carmine aluminium lake; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 6000; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. treatment of ophthalmic zoster. treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes in immunocompromised patients with creatinine clearance of > 15 ml/min. for the reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions). for prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - esomeprazole magnesium, quantity: 41.4 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: povidone; macrogol 400; macrogol 6000; microcrystalline cellulose; diethyl phthalate; hypromellose phthalate; crospovidone; macrogol 4000; sodium stearylfumarate; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; maize starch; sucrose - gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazolesolution administered by intravenous infusion,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer